{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:54:11Z","timestamp":1791024851756,"version":"4.1.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite advances in therapy, chronic spontaneous urticaria (CSU) remains a challenging disease with a significant impact. Although antihistamines, anti-IgE therapy and immunosuppressants form the basis of treatment, there are still substantial gaps in diagnosis, endotyping, prediction of therapeutic response and implementation of international guidelines.<\/jats:p>\n                  <jats:p>Newly licensed CSU therapeutic agents, such as Bruton tyrosine kinase (BTK) inhibitors and anti-interleukin-4 receptor alpha (anti-IL4R\u03b1) agents, offer hope to patients who do not respond to treatment. However, we currently lack validated biomarkers of disease-specific features to determine which patient should receive which therapy, and the optimal positioning of these agents within the treatment sequence remains undefined.<\/jats:p>\n                  <jats:p>This narrative review examines the ongoing challenges in CSU management and proposes a more integrated, personalised and patient-centred approach.<\/jats:p>","DOI":"10.1093\/bjd\/ljag389","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:44:01Z","timestamp":1789213441000},"source":"Crossref","is-referenced-by-count":0,"title":["Gaps in Current Chronic Spontaneous Urticaria (CSU) Management"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8726-6658","authenticated-orcid":false,"given":"Ang\u00e8le","family":"Soria","sequence":"first","affiliation":[{"name":"Sorbonne University, Dermatology and Allergology Department, Tenon Hospital, UCARE and ACARE Centers , Paris ,","place":["France"]},{"name":"INSERM 1155 , Paris ,","place":["France"]},{"name":"Tenon Hospital UCARE and ACARE Centers , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,3]]},"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag389\/71576048\/ljag389.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag389\/71576048\/ljag389.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:18:43Z","timestamp":1791022723000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article\/doi\/10.1093\/bjd\/ljag389\/8860201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag389","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"article-number":"ljag389"}}